In Depth 3 Sep 2025 How are biotechs tackling malaria? …making of the monoclonal antibody MAM01 along with the University of Maryland School of Medicine in the U.S. It is an engineered version of a human monoclonal antibody that is… September 3, 2025 - 13 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Interview 4 Sep 2017 Meet this Blockbuster Developer turned Partner at a Headlining VC Kevin Johnson told me the story and lessons of his career, from CTO of Cambridge Antibody Technology to General Partner at Medicxi. Since starting his biotech career as the lead… September 4, 2017 - 7 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 28 Sep 2022 Pheon Therapeutics launches with $68M in series A funding for treatment of solid tumors Pheon Therapeutics launched today (September 28) following the closing of a $68 million series A funding back in March. The investment will allow antibody-drug conjugate (ADC) specialist Pheon to advance… September 28, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2025 The ESMO 2025 digest: Is oncology in good shape? The European Society for Medical Oncology(ESMO) Congress 2025 in Berlin (17–21 October) delivered a week of consequential but not always uniform readouts. Antibody-drug conjugates (ADCs) stayed in the spotlight, most notably with disitamab vedotin… October 24, 2025 - 6 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 3 Aug 2022 Patients with advanced cancer set to benefit from ProfoundBio’s new drug Patients with ovarian, endometrial, breast, non-small cell lung cancers and mesothelioma could benefit from an antibody drug conjugate (ADC) after clearance of an investigational new drug (IND) was approved by… August 3, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 21 Dec 2022 Watch: Araris Biotech at Bio-Europe …further development and advancement of Araris’ antibody-drug conjugate (ADC) candidates, created using the Company’s proprietary linker technology, as Araris moves closer towards clinical development. At Bio-Europe, we chatted with Philipp… December 21, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 Aug 2022 CSL gets positive results for preventive treatment in patients with hereditary angioedema Hereditary angioedema (HAE), a condition that causes recurrent attacks of severe swelling, could be prevented by a monoclonal antibody after positive top line phase 3 results were reported. Garadacimab, biotech… August 18, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jun 2017 Next-Gen Drug Conjugates Bank €46M in Series B with American Investors …the drug behaves like an antibody-drug conjugate with an engineered bicyclic peptide instead of an antibody. BT1718’s small size of 1.5 to 2 kDa allows it to enter a solid… June 1, 2017 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 30 Nov 2022 SOTIO exercises option on ADC program SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, has exercised its first of five exclusive, target-specific options with LegoChem Biosciences (LCB) for antibody-drug conjugate (ADC) SOT106, which… November 30, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Interview 4 Oct 2017 4th-Generation ADCs: Meet the Swiss Startup Perfecting the Technology ADC development has progressed to the fourth generation. Serial entrepreneur Ulf Grawunder told me what NBE is doing differently from its predecessors. Ever since the first antibody-drug conjugate (ADC) was… October 4, 2017 - 5 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jun 2018 Update: Yet Another ADC Company Makes Bank, This Time in Series B …Basel-based biotech making its debut as a player in antibody drug conjugates (ADCs). It just raised 20M CHF in Series B, with PPF leading the way. With the funds, NBE… June 29, 2018 - 3 minutesmins - By Editorial Team Share WhatsApp Twitter Linkedin Email
News and Trends 14 Oct 2022 Mablink Bioscience receives €31M series A funding for ADC pipeline French biotech company Mablink Bioscience has raised €31 million ($30.3 million) in series A funding to advance its lead candidate to the clinic and to build a pipeline of antibody… October 14, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email